Dynavax TechnologiesDVAX
DVAX
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
68% more call options, than puts
Call options by funds: $8.17M | Put options by funds: $4.87M
31% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 29
25% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]
20% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 80
16% more capital invested
Capital invested by funds: $1.44B [Q3] → $1.67B (+$224M) [Q4]
2% more funds holding
Funds holding: 250 [Q3] → 254 (+4) [Q4]
0.32% more ownership
Funds ownership: 98.97% [Q3] → 99.29% (+0.32%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
3%
downside
Avg. target
$25
139%
upside
High target
$33
220%
upside
3 analyst ratings
2 positive
67%
0 neutral
0%
1 negative
33%
Goldman Sachs Paul Choi 53% 1-year accuracy 8 / 15 met price target | 3%downside $10 | Sell Maintained | 17 Apr 2025 |
Citizens Capital Markets Jason Butler 24% 1-year accuracy 10 / 42 met price target | 220%upside $33 | Market Outperform Maintained | 21 Feb 2025 |
HC Wainwright & Co. Edward White 24% 1-year accuracy 36 / 149 met price target | 201%upside $31 | Buy Reiterated | 21 Feb 2025 |
Financial journalist opinion
Based on 4 articles about DVAX published over the past 30 days
Neutral
PRNewsWire
2 days ago
Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders
Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Highlights Record Financial and Operational Results, Balanced Capital Allocation Strategy andMeaningful Board Refreshment Underscores Deep Track's Value Destructive, Short-Term Focus and Unnecessary Proxy Contest EMERYVILLE, Calif. , April 17, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has filed definitive proxy materials with the Securities and Exchange Commission ("SEC") in connection with its upcoming Annual Meeting of Stockholders scheduled to be held on June 11, 2025.
Neutral
Business Wire
3 days ago
Deep Track Capital Comments on Dynavax Technologies' Rejection of Most Recent Settlement Offer
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”) is one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.34% of the Company's outstanding shares. Today Deep Track commented on the Company's disclosure that the Board of Directors (the “Board”) has rejected a settlement proposal in connection with its nomination of four highly qualif.
Neutral
PRNewsWire
2 weeks ago
Dynavax Files Preliminary Proxy Statement
Dynavax's Board is Overseeing Record Operational and Financial Performance Outlines Extensive Engagement with Deep Track and Multiple Attempts to Reach a Resolution EMERYVILLE, Calif. , April 3, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today filed its preliminary proxy materials with the Securities and Exchange Commission ("SEC") in connection with its upcoming Annual Meeting of Stockholders ("the 2025 Annual Meeting").
Positive
Zacks Investment Research
4 weeks ago
Why Dynavax Technologies (DVAX) Stock Might be a Great Pick
Dynavax Technologies (DVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See an 83.1% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?
The consensus price target hints at an 83.1% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Business Wire
1 month ago
Deep Track Capital Sends Letter to Dynavax Technologies' Board of Directors
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.34% of the Company's outstanding shares, today sent a letter to the Company's Board of Directors (the “Board”) related to Deep Track's nomination of four highly qualified candidates for election to the Company's Board of Directors.
Neutral
PRNewsWire
1 month ago
Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase
Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure $225 million of convertible notes due in 2030 issued, including an exchange for the retirement of ~$185 million of existing convertible notes due in 2026 and ~$40 million of new money Dynavax repurchased ~$8 million of the Company's common stock in connection with this transaction EMERYVILLE, Calif. , March 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, has entered into privately negotiated exchange and subscription agreements (the "Exchange Agreements") with a limited number of holders of its outstanding 2.50% Convertible Senior Notes due 2026 (the "2026 Notes") and one new investor, pursuant to which the Company will issue $225 million aggregate principal amount of 2.0% Convertible Senior Notes due 2030 (the "New Notes") comprised of (i) an exchange for the retirement of approximately $185 million in aggregate principal amount of existing 2026 Notes, and (ii) approximately $40 million of New Notes issued to existing holders and one new investor (the "Transactions").
Positive
Seeking Alpha
1 month ago
Dynavax Technologies: A Post-Earnings Assessment With Growing Market Share
Dynavax Technologies posted solid Q4 results and FY 2025 guidance late in February, with Heplisav-B driving revenue growth and profitability. Heplisav-B's market share continues to grow due to its superior efficacy and compliance compared to previous hepatitis B vaccines. Heplisav-B should eventually garner 60% of a market that is predicted to grow to $900 million in the U.S. by 2030.
Neutral
PRNewsWire
1 month ago
Dynavax to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif. , Feb. 25, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 1:10 p.m.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 81.92%: Read This Before Placing a Bet
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 81.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Charts implemented using Lightweight Charts™